Have a personal or library account? Click to login
Intravenous treatment adherence of patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemic: experience of a single center Cover

Intravenous treatment adherence of patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemic: experience of a single center

Romanian Journal of Internal Medicine
Volume 60 (2022): Issue 3 (September 2022)
By: Hatice Ecem Konak,  Berkan Armağan,  Serdar Can Güven,  Ebru Atalar,  Özlem Karakaş,  Serdar Esmer,  Mehmet Akif Eksin,  Bünyamin Polat,  Hakan Apaydin,  Kevser Gök,  İsmail Doğan,  Abdulsamet Erden,  Yüksel Maraş,  Orhan Küçükşahin,  Ahmet Omma and  Şükran Erten  
Open Access
|Sep 2022

References

  1. 1. KİM Y, AHN E, LEE S, LİM DH, KİM A, LEE SG., et al. Changing Patterns of Medical Visits and Factors Associated with No-show in Patients with Rheumatoid Arthritis during COVID-19 Pandemic. J Korean Med Sci. 2020;35(48):e423.10.3346/jkms.2020.35.e423
    Search in Google ScholarBack to article
  2. 2. HASÖKSÜZ M, KİLİÇ S, SARAÇ F. Coronaviruses and SARS-CoV-2. Turkish journal of medical sciences. 2020;50(SI-1):549–56.10.3906/sag-2004-127
    Search in Google ScholarBack to article
  3. 3. POPE JE. What does the COVID-19 pandemic mean for rheumatology patients? Current treatment options in rheumatology. 2020;6(2):71–4.10.1007/s40674-020-00145-y
    Search in Google ScholarBack to article
  4. 4. RİCHEZ C, LAZARO E, LEMOİNE M, TRUCHETET M-E, SCHAEVERBEKE T. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. Joint Bone Spine. 2020;87(3):187.10.1016/j.jbspin.2020.03.010
    Search in Google ScholarBack to article
  5. 5. SAADOUN D, VİEİRA M, VAUTİER M, BARALİAKOS X, ANDREİCA I, DA SİLVA JA., et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. The Lancet Rheumatology. 2021.10.1016/S2665-9913(21)00112-0
    Search in Google ScholarBack to article
  6. 6. PABLOS JL, GALİNDO M, CARMONA L, LLEDÓ A, M RETUERTO, BLANCO R., et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis, 2020. 79(12): p. 1544–1549.10.1136/annrheumdis-2020-218296743018532796045
    Search in Google ScholarBack to article
  7. 7. MONTERO F, MARTÍNEZ-BARRİO J, SERRANO-BENAVENTE B, GONZÁLEZ T, RİVERA J, MOLİNA COLLADA J., et al. Coronavirusdisease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int, 2020. 40(10): p. 1593–1598.10.1007/s00296-020-04676-4742525432794113
    Search in Google ScholarBack to article
  8. 8. SANTOS CS, FÉRNANDEZ XC, MORALES CM, ÁLVAREZ ED, CASTRO CÁ, ROBLES AL., et al. Biologicalagentsforrheumaticdiseases in theoutbreak of COVID-19: friendorfoe? RMD Open, 2021. 7(1).10.1136/rmdopen-2020-001439781340733455920
    Search in Google ScholarBack to article
  9. 9. Turkish Rheumatology Association Coronavirus (Covid-19) Outbreak Recommendations (2020) March 27th Title.
    Search in Google ScholarBack to article
  10. 10. GABRİEL SE, MİCHAUD K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis research & therapy. 2009;11(3):229.10.1186/ar2669271409919519924
    Search in Google ScholarBack to article
  11. 11. SFRİSO P, GHİRARDELLO A, BOTSİOS C, TONON M, ZEN M, BASSİ N., et al. Infections and autoimmunity: the multifaceted relationship. Journal of leukocyte biology. 2010;87(3):385–95.10.1189/jlb.070951720015961
    Search in Google ScholarBack to article
  12. 12. GİRSCHİCK HJ, GUİLHERME L, INMAN RD, LATSCH K, RİHL M, SHERER Y., et al. Bacterial triggers and autoimmune rheumatic diseases. Clinical and experimental rheumatology. 2008;26(1 Suppl 48):S12–7.
    Search in Google ScholarBack to article
  13. 13. SEYAHİ E, POYRAZ BC, SUT N, AKDOGAN S, HAMURYUDAN V. The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. Rheumatol Int. 2020;40(8):1229–38.10.1007/s00296-020-04626-0
    Search in Google ScholarBack to article
  14. 14. European League Against Rheumatism (EULAR), Guidance for Patients during Covid-19 Outbreak, (2020) Updated March 17th Internet.https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm. April 25th, 2020
    Search in Google ScholarBack to article
  15. 15. American College of Rheumatology (Acr), Guidance for Patients during Covid-19Outbreak, (2020) Updated April 14th.
    Search in Google ScholarBack to article
  16. 16. British Society for Rheumatology (Bsr), Guidance for Patients during Covid-19 Outbreak, (2020) Updated July 29th.
    Search in Google ScholarBack to article
  17. 17. VENERİTO V, LOPALCO G, IANNONE F. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatology international. 2020;40(5):827–8.10.1007/s00296-020-04566-9
    Search in Google ScholarBack to article
  18. 18. COSKUN BN, YAGİZ B, PEHLİVAN Y, DALKİLİC E. Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic. Advances in rheumatology (London, England). 2021;61(1):55.10.1186/s42358-021-00211-6
    Search in Google ScholarBack to article
  19. 19. FAVALLİ EG, MONTİ S, INGEGNOLİ F, BALDUZZİ S, CAPORALİ R, MONTECUCCO C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis & Rheumatology. 2020;72(10):1600–6.10.1002/art.41388
    Search in Google ScholarBack to article
  20. 20. ROSENBAUM JT, HAMİLTON H, CHOİ D, WEİSMAN MH, REVEİLLE JD, WİNTHROP KL. Biologics, spondylitis and COVID-19. Annals of the rheumatic diseases. 2020;79(12):1663–5.10.1136/annrheumdis-2020-217941
    Search in Google ScholarBack to article
  21. 21. LÓPEZ-MEDİNA C, LADEHESA-PİNEDA L, GÓMEZ-GARCÍA I, PUCHE-LARRUBİA M, SEQUÍ-SABATER JM, ARMENTEROS-ORTİZ P., et al. Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients. Joint Bone Spine. 2021;88(2):105085.10.1016/j.jbspin.2020.105085
    Search in Google ScholarBack to article
  22. 22. KALYONCU U, PEHLİVAN Y, AKAR S, KAŞİFOĞLU T, KİMYON G, KARADAĞ Ö., et al. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish journal of medical sciences. 2021;51(4):1615–23.10.3906/sag-2012-5
    Search in Google ScholarBack to article
  23. 23. COSTANTİNO F, BAHİER L, TARANCÓN LC, LEBOİME A, VİDAL F, BESSALAH L., et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine. 2021;88(1):105095.10.1016/j.jbspin.2020.105095
    Search in Google ScholarBack to article
  24. 24. LANDEWÉ RB, MACHADO PM, KROON F, BİJLSMA HW, BURMESTER GR, CARMONA L., et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the rheumatic diseases. 2020;79(7):851–8.10.1136/annrheumdis-2020-217877
    Search in Google ScholarBack to article
  25. 25. MEHTA P, PORTER JC, CHAMBERS RC, ISENBERG DA, REDDY V. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? The Lancet Rheumatology. 2020;2(10):e589–e90.10.1016/S2665-9913(20)30270-8
    Search in Google ScholarBack to article
  26. 26. EMMİ G, BETTİOL A, MATTİOLİ I, SİLVESTRİ E, Dİ SCALA G, URBAN ML., et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev, 2020. 19(7): p. 102575.10.1016/j.autrev.2020.102575720013432376395
    Search in Google ScholarBack to article
  27. 27. STRANGFELD A, SCHÄFER M, GİANFRANCESCO MA, LAWSON-TOVEY S, LİEW JW, LJUNG L., et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930–42.10.1136/annrheumdis-2020-219498784321133504483
    Search in Google ScholarBack to article
  28. 28. TEPASSE PR, HAFEZİ W, LUTZ M, KÜHN J, WİLMS C, WİEWRODT R., et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. British journal of haematology. 2020;190(2):185–8.10.1111/bjh.16896730095032557623
    Search in Google ScholarBack to article
  29. 29. ZHAO J, YUAN Q, WANG H, LİU W, LİAO X, SU Y., et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(16):2027–34.10.1093/cid/ciaa344718433732221519
    Search in Google ScholarBack to article
  30. 30. SCHETT G, MANGER B, SİMON D, CAPORALİ R. COVID-19 revisiting inflammatory pathways of arthritis. Nature Reviews Rheumatology. 2020:1-6.10.1038/s41584-020-0451-z730438132561873
    Search in Google ScholarBack to article
  31. 31. CAMPBELL L, CHEN C, BHAGAT SS, PARKER RA, ÖSTÖR AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford, England). 2011;50(3):552–62.10.1093/rheumatology/keq34321078627
    Search in Google ScholarBack to article
  32. 32. CARRARA G, BORTOLUZZİ A, SAKELLARİOU G, SİLVAGNİ E, ZANETTİ A, GOVONİ M., et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clinical and experimental rheumatology. 2019;37(1):60–6.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/rjim-2022-0010 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Journal RSS Feed
Language: English
Page range: 173 - 181
Submitted on: Apr 28, 2022
Published on: Sep 22, 2022
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
coronavirus,
infliximab,
intravenous infusion,
patient adherence,
rheumatology,
rituximab
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Cardiology,
Gastroenterology,
Rheumatology

© 2022 Hatice Ecem Konak, Berkan Armağan, Serdar Can Güven, Ebru Atalar, Özlem Karakaş, Serdar Esmer, Mehmet Akif Eksin, Bünyamin Polat, Hakan Apaydin, Kevser Gök, İsmail Doğan, Abdulsamet Erden, Yüksel Maraş, Orhan Küçükşahin, Ahmet Omma, Şükran Erten, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 60 (2022): Issue 3 (September 2022)Next article